Editorial: vedolizumab as a treatment and cause of extra‐intestinal manifestations of inflammatory bowel disease.

The authors discuss a study published in an issue of the periodical focusing on the role of vedolizumab in treatment and cause of extra-intestinal manifestations of inflammatory bowel disease. Topics discussed include the lesions such as pyoderma gangrenosum, erythema nodosum and aphthous stomatitis; the prevalence of peripheral arthritis, ankylosing spondylitis and sacroiliitis; and the lack of efficacy of anti-rheumatic agents (DMARDs) such as methotrexate and sulphasalazine in treatment.